| SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Islam Saqib | Chief Executive Officer | Oct 20 | Sale | 58.67 | 10,083 | 591,527 | 779,218 | Oct 20 07:14 PM | | Islam Saqib | Chief Executive Officer | Oct 19 | Sale | 58.81 | 14,077 | 827,873 | 769,135 | Oct 19 07:27 PM | | Islam Saqib | Chief Executive Officer | Oct 18 | Sale | 58.59 | 38,340 | 2,246,505 | 783,212 | Oct 19 07:27 PM | | Smith L. Mary | Chief Development Officer | Oct 13 | Option Exercise | 2.30 | 10,000 | 23,000 | 177,511 | Oct 13 08:24 PM | | Smith L. Mary | Chief Development Officer | Oct 13 | Sale | 55.97 | 10,000 | 559,675 | 167,511 | Oct 13 08:24 PM | | Pichl Daniel | Chief People Officer | Sep 08 | Option Exercise | 43.10 | 2,320 | 99,992 | 9,236 | Sep 09 05:15 PM | | Bain Capital Life Sciences Inv | 10% Owner | Aug 10 | Sale | 70.25 | 1,000,000 | 70,250,000 | 4,831,307 | Aug 12 08:38 PM | | Islam Saqib | Chief Executive Officer | Jul 20 | Sale | 77.68 | 18,572 | 1,442,751 | 821,552 | Jul 20 07:34 PM | | Islam Saqib | Chief Executive Officer | Jul 19 | Sale | 76.09 | 43,928 | 3,342,438 | 840,124 | Jul 20 07:34 PM | | Smith L. Mary | Chief Development Officer | Jul 13 | Option Exercise | 2.30 | 10,000 | 23,000 | 177,511 | Jul 14 04:28 PM | | Smith L. Mary | Chief Development Officer | Jul 13 | Sale | 80.88 | 10,000 | 808,777 | 167,511 | Jul 14 04:28 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jul 01 | Sale | 85.01 | 15,959 | 1,356,675 | 6,028,307 | Jul 06 04:42 PM | | Edris Badreddin | Chief Operating Officer | Jul 01 | Sale | 85.35 | 32,000 | 2,731,088 | 301,541 | Jul 01 06:30 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 28 | Sale | 85.17 | 6,502 | 553,775 | 6,044,266 | Jun 30 09:01 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 25 | Sale | 85.14 | 22,334 | 1,901,517 | 6,050,768 | Jun 25 07:11 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 24 | Sale | 85.22 | 34,200 | 2,914,524 | 6,073,102 | Jun 25 07:11 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 23 | Sale | 85.00 | 100 | 8,500 | 6,107,302 | Jun 25 07:11 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 10 | Sale | 85.09 | 30,852 | 2,625,197 | 6,107,402 | Jun 14 05:58 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 09 | Sale | 85.33 | 5,049 | 430,831 | 6,138,254 | Jun 09 06:26 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 08 | Sale | 85.37 | 42,633 | 3,639,579 | 6,143,303 | Jun 09 06:26 PM | | ORBIMED ADVISORS LLC | 10% Owner | Jun 07 | Sale | 84.90 | 371 | 31,498 | 6,185,936 | Jun 09 06:26 PM | | SQUINTO STEPHEN P | Director | Apr 28 | Sale | 76.20 | 19,231 | 1,465,437 | 125,728 | Apr 28 08:18 PM | | SQUINTO STEPHEN P | Director | Apr 27 | Sale | 75.05 | 201 | 15,085 | 144,959 | Apr 28 08:18 PM | | Islam Saqib | Chief Executive Officer | Apr 20 | Sale | 66.39 | 24,075 | 1,598,279 | 884,052 | Apr 20 06:51 PM | | Islam Saqib | Chief Executive Officer | Apr 19 | Sale | 69.04 | 38,425 | 2,652,827 | 908,127 | Apr 20 06:51 PM | | SQUINTO STEPHEN P | Director | Apr 15 | Sale | 75.01 | 1,057 | 79,291 | 145,160 | Apr 19 06:07 AM | | SQUINTO STEPHEN P | Director | Apr 14 | Sale | 75.08 | 511 | 38,365 | 146,217 | Apr 19 06:07 AM | | Smith L. Mary | Chief Development Officer | Apr 13 | Option Exercise | 2.30 | 10,000 | 23,000 | 177,511 | Apr 13 08:21 PM | | Smith L. Mary | Chief Development Officer | Apr 13 | Sale | 68.07 | 10,000 | 680,723 | 167,511 | Apr 13 08:21 PM | | Bain Capital Life Sciences Inv | 10% Owner | Mar 09 | Sale | 71.50 | 1,450,000 | 103,675,000 | 5,831,307 | Mar 11 04:30 PM | | ORBIMED ADVISORS LLC | 10% Owner | Mar 01 | Sale | 83.19 | 1,220,000 | 101,491,800 | 6,186,307 | Mar 03 06:55 PM | | Edris Badreddin | Chief Operating Officer | Jan 25 | Sale | 84.07 | 32,000 | 2,690,282 | 261,542 | Jan 26 04:31 PM | | Smith L. Mary | Chief Development Officer | Jan 20 | Option Exercise | 2.23 | 10,000 | 22,267 | 177,511 | Jan 21 04:31 PM | | Smith L. Mary | Chief Development Officer | Jan 20 | Sale | 78.70 | 10,000 | 787,016 | 167,511 | Jan 21 04:31 PM | | Islam Saqib | Chief Executive Officer | Jan 20 | Sale | 78.75 | 2,199 | 173,180 | 1,222,997 | Jan 21 04:30 PM | | Islam Saqib | Chief Executive Officer | Jan 19 | Sale | 78.54 | 60,301 | 4,736,209 | 1,225,196 | Jan 21 04:30 PM |
|
